China: Evolving Dynamics of the CDMO Landscape
This webinar originally aired as part of CPhI Discover - 17-28 May 2021
An overview of global CDMO markets – positioning, strengths and weaknesses of the Chinese CDMO industry.
The Evolution of the Chinese CDMO industry, from CMO to CDMO, from starting materials, intermediates to API, drug substance to drug products, generic drugs to NCE/NME – what innovations are on the horizon?
The challenges and opportunities of the Chinese CDMO industry – Growth dynamics, the competitive landscape and regulatory barriers.
Building a successful CDMO amidst fierce competition, what are the critical attributes of a successful CMC team?
How to strategically build technology platforms and capabilities which meet global compliance standards, what are the key requirements for facilities and systems?
Langhua Pharma’s own strategy towards becoming a leading CDMO in China, what does the future look like?